We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02468908
First Posted: June 11, 2015
Last Update Posted: February 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Celerion
Information provided by (Responsible Party):
Savara Inc.
  Purpose
This is a randomized, double-blind, placebo-controlled, single ascending (SAD), and multiple ascending dose (MAD) study conducted at a single clinical site within the UK. Healthy male and female subjects (on non-child bearing potential) will be enrolled to investigate single inhaled doses of molgramostim at 3 dose levels (Part 1) and multiple inhaled doses at 2 dose levels (Part 2). The 2 doses in the multiple ascending dose regimens will be administered once daily (QD) for 6 consecutive days. The clinical indication for inhaled molgramostim is the treatment of respiratory diseases such as aPAP, bronchiectasis and cystic fibrosis. The Clinical trial will involve 42 healthy participants. The trial is expected to last approximately 4 months.

Condition Intervention Phase
Pulmonary Alveolar Proteinosis Bronchiectasis Cystic Fibrosis Acute Respiratory Distress Syndrome Drug: Molgramostim Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Single-Centre, Single Ascending Dose and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Molgramostim When Administered by Inhalation to Healthy Adult Subjects

Resource links provided by NLM:


Further study details as provided by Savara Inc.:

Primary Outcome Measures:
  • Number and severity of treatment-emergent Adverse Events (AEs) following single and multiple inhaled doses of molgramostim [ Time Frame: 1-6 days ]

Secondary Outcome Measures:
  • PK parameters: Area under the plasma concentration time curve (AUC), Peak Peak Plasma concentration - Cmax, Time to reach maximum observed serum concentration - tmax [ Time Frame: 1-6 days ]
  • PK parameters: Apparent terminal elimination rate constant - k(el) and Apparent terminal elimination rate constant - t(1/2) [ Time Frame: 1-6 days ]

Other Outcome Measures:
  • Development of antibodies to rhGM-CSF [ Time Frame: 28 days ]
  • Change from baseline in Whole Blood Celle Count (WBCC) [ Time Frame: 7 days ]
  • Change from baseline in exhaled fraction of Nitric Oxide (FeNO) measurements [ Time Frame: 7 days ]
  • Change from baseline in QT/QTc intervals [ Time Frame: 7 days ]

Enrollment: 42
Study Start Date: May 2015
Study Completion Date: October 2015
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Molgramostim nebuliser solution, inhaled
Single dose 150, 300 and 600 ug, multiple dose 300 and 600 ug for 6 days
Drug: Molgramostim
Other Name: Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF)
Placebo Comparator: Nebuliser solution, inhaled
Inhaled nebuliser solution
Drug: Placebo
Other Name: Nebuliser solution

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy, adult, male or female, 18- 55 years of age, inclusive, at screening.
  2. Life-long non smoker who has not used nicotine containing products.
  3. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening.
  4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, spirometry, vital signs, or ECGs, as deemed by the PI.
  5. Females must be of non-child bearing potential who must have undergone one of the following sterilization procedures at least 6 months prior to dosing in Part 1 or prior to the first dose in Part 2:

    • hysteroscopic sterilization;
    • bilateral tubal ligation or bilateral salpingectomy;
    • hysterectomy;
    • bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to dosing in Part 1 or prior to the first dose in Part 2, and FSH serum levels consistent with postmenopausal status as per PI's judgment.
  6. A non vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study medication. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to study start. A male who has been vasectomized less than 4 months prior to study start must follow the same restrictions as a non vasectomized male).
  7. If male must agree not to donate sperm from dosing in Part 1 or from the first dose in Part 2, until 90 days following last dose.
  8. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

Exclusion Criteria:

  1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of screening visit or expected during the conduct of the study.
  2. History or presence of clinically significant medical condition(s) (including ongoing active infections) or psychiatric condition(s) or disease(s) in the opinion of the PI.
  3. History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  4. Abnormal spirometry test results, in the opinion of the PI.
  5. History of severe or unexplained adverse reactions during aerosol delivery of any medicinal product.
  6. History or presence of alcoholism or drug abuse within the past 2 years prior to screening.
  7. History or presence of hypersensitivity or idiosyncratic reaction to molgramostim or to related compounds (i.e., Growgen®, Leucomax®, Leukine®, Topleucon™).
  8. Clinically significant history or presence of ECG abnormalities such as second- or third degree atrioventricular block, evidence, or family history of prolonged QT syndrome.
  9. Allergy to bandaids, adhesive dressing, or medical tape.
  10. Positive urine drug at screening or check in.
  11. Positive alcohol test at check-in.
  12. Drink alcohol in excess of 21 units per week for males or 14 units per week for females, with one unit = 150 mL of wine or 360 mL of beer or 45 mL of 45% alcohol.
  13. Positive urine cotinine at screening and check-in.
  14. Positive results at screening for HIV, HBsAg, or HCV.
  15. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
  16. Seated heart rate is lower than 45 bpm or higher than 99 bpm at screening.
  17. QTcF interval is >430 msec (males) or >450 msec (females) at screening or deemed clinically abnormal by the PI.
  18. Unable to refrain from or anticipates the use of:

    • Any drug, including prescription and non prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to dosing in Part 1 or prior to the first dose in Part 2, and throughout the study. Hormone replacement therapy (HRT) is not permitted in this study and within 3 months prior to screening. During the study paracetamol (up to 2 g per 24 hours) may be administered at the discretion of the PI.
    • Any drugs known to be significant inducers of CYP enzymes and/or P gp, including St. John's Wort, for 28 days prior to dosing in Part 1 or prior to the first dose in Part 2, and throughout the study. Appropriate sources will be consulted by the PI or designee to confirm lack of PK/PD interaction with study drug.
  19. Have been on a diet incompatible with the on study diet, in the opinion of the PI, within the 28 days prior to the first dose of study drug, and throughout the study.
  20. Haemoglobin or total WBC outside the normal range at screening.
  21. Donation of blood or plasma within 90 days prior to dosing in Part 1 or prior to the first dose in Part 2.
  22. Donation of bone marrow within the last 6 months prior to dosing in Part 1 or prior to the first dose in Part 2.
  23. Participation in another clinical trial within 90 days prior to dosing in Part 1 or prior to the first dose in Part 2.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02468908


Locations
United Kingdom
Celerion
Belfast, United Kingdom, BT9 6AD
Sponsors and Collaborators
Savara Inc.
Celerion
Investigators
Principal Investigator: Johnston Steward, MD Celerion
  More Information

Responsible Party: Savara Inc.
ClinicalTrials.gov Identifier: NCT02468908     History of Changes
Other Study ID Numbers: MOL-001
First Submitted: June 3, 2015
First Posted: June 11, 2015
Last Update Posted: February 23, 2017
Last Verified: November 2015

Additional relevant MeSH terms:
Cystic Fibrosis
Respiratory Distress Syndrome, Newborn
Respiratory Distress Syndrome, Adult
Acute Lung Injury
Bronchiectasis
Pulmonary Alveolar Proteinosis
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Respiration Disorders
Infant, Premature, Diseases
Lung Injury
Bronchial Diseases
Pharmaceutical Solutions
Molgramostim
Antineoplastic Agents